Modelling of DARPP-32 regulation to understand intracellular signaling in psychiatric disease

Pharmacopsychiatry

Volumn 41, Issue SUPPL. 1, 2008, Pages

  Lindskog, Mia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DOPAMINE; G PROTEIN COUPLED RECEPTOR; NEUROTRANSMITTER; PHOSPHOPROTEIN DARPP 32; SEROTONIN;

COMPUTER MODEL; DRUG RECEPTOR BINDING; MENTAL DISEASE; MOLECULAR INTERACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

ANIMALS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HUMANS; MENTAL DISORDERS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 54749143911     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1080903     Document Type: Review

References (56)

1. Adams AC, Keefe KA. Examination of the involvement of protein kinase A in D2 dopamine receptor antagonist-induced immediate early gene expression. Journal of Neurochemistry 2001; 77 (1): 326-335
2. Agid Y, Buzsaki G, Diamond DM et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007; 6 (3): 189-201
3. Ahn J-H, MacAvoy T, Rakhilin SV, Nishi A, Greengard P, Nairn AC. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56{delta} subunit. Proceedings of the National Academy of Sciences 2007; 104 (8): 2979-2984
4. Ahn J-H, Sung JY, MacAvoy T et al. The B″/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proceedings of the National Academy of Sciences 2007; 104 (23): 9876-9881
5. Akira Y, Nagahide T, Shinichi S et al. Genetic analysis of the gene coding for DARPP-32 (PPP1R1B) in Japanese patients with schizophrenia or bipolar disorder. Schizophrenia research 2007
6. Albert KA, Hemmings Jr HC, Adamo AIB et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002; 59 (8): 705-712
7. Baracskay KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 2006; 60 (4): 271-279
8. Barbano PE, Spivak M, Flajolet M, Nairn AC, Greengard P, Greengard L. A mathematical tool for exploring the dynamics of biological networks. Proceedings of the National Academy of Sciences 2007; 104 (49): 19169-19174
9. Beaulieu J-M, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RP, Caron MG. An Akt/[beta]-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122 (2): 261-273
10. Bhalla US. Signaling in small subcellular volumes. I. stochastic and diffusion effects on individual pathways. Biophys J 2004; 87 (2): 733-744
11. Bhalla US, Iyengar R. Emergent properties of networks of biological signaling pathways. Science 1999; 283 (5400): 381-387
12. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002; 297 (5583): 1018-1023
13. Bibb JA, Snyder GL, Nishi A et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999; 402 (6762): 669-671
14. Blackwell KT. Modeling calcium concentration and biochemical reactions. Brains, Minds and Media 2005;1: http://www.brainsminds-media.org/archive/224/
15. Carlsson A. The Neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl. 1); S10-S14
16. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interacttions between monoamines, glutamate, and GABA in schizophrenia: New Evidence. Annu Rev Pharmacol Toxicol 2001; 41 (1): 237-260
17. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 6 (3): 241-246
18. Changeux J-P, Dehaene S. Hierarchical neuronal modeling of cognitive functions: from synaptic transmission to the Tower of London. Int J Psychophysiol 2000; 35 (2-3): 179-187
19. D'Alcantara P, Schiffmann SN, Swillens S. Bidirectional synaptic plasticity as a consequence of interdependent Ca2+-controlled phosphorylation and dephosphorylation pathways. Eur J Neurosci 2003; 17 (12): 2521-2528
20. Desdouits F, Sicillano JC, Greengard P, Girauit JA. Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc Natl Acad Sci USA 1995; 92 (7): 2682-2685
21. Durstewitz D. A few important points about dopamine's role in neural network dynamics. Pharmacopsychiatry 2006; 39 (Suppl): S72-S75
22. Fernandez R, Schiappa R, Girault J-A, LeNovere N. DARPP-32 is a robust integrator of dopamine and glutamate signals. PLoS Comput Biol 2006; 2 (12): e176
23. Fienberg AA, Hiroi N, Mermelstein PG et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998; 281 (5378): 838-842
24. Flores-Hernandez J, Hernandez S, Snyder GL et al. D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade. J Neurophysiol 2000; 83 (5): 2996-3004
25. Girault JA, Hemmings Jr HC, Williams KR, Nairn AC, Greengard P. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J Biol Chem 1989; 264 (36): 21748-21759
26. Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294 (5544): 1024-1030
27. Hakansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 2006; 96 (2): 482-488
28. Halpain S, Girault JA, Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 1990; 343 (6256): 369-372
29. Hemmings Jr HC, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984; 310 (5977): 503-505
30. Hernandez-Lopez S, Tkatch T, Perez-Garci E et al. D2 dopamine receptors in striatal medium spiny neurons reduce L-Type Ca2+currents and excitability via a novel PLC{beta}1-IP3-calcineurin-signaling cascade. J Neurosci 2000; 20 (24): 8987-8995
31. Hu J-X, Yu L, Shi Y-Y et al. An association study between PPP1R1B gene and schizophrenia in the Chinese population. Prog Neuro-Psychoph 2007; 31 (6): 1303-1306
32. Ishikawa M, Mizukami K, Iwakiri M, Asada T. Immunohistochemical and immunoblot analysis of dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuro-Psychoph 2007; 31 (6): 1177-1181
33. Leuner K, Müller W. Dopamine in the prefrontal cortex and its different modulation by conventional and atypical antipsychotics. Pharmacopsychiatry 2007; 40 (Suppl. 1): S17-S26
34. Lindskog M, Kim M, Wikstrom MA, Blackwell KT, Kotaleski JH. Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation. PLoS Comput Biol 2006; 2 (9): e119
35. Lindskog M, Svenningsson P, Fredholm B, Greengard P, Fisone G. Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur J Neurosci 1999; 11 (6): 2182-2186
36. Lindskog M, Svermingsson P, Pozzi L et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 2002; 418 (6899): 774-778
37. Meyer-Lindenberg A, Straub R, Lipska B et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007; 117 (3): 672-682
38. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003; 3 (1): 27-39
39. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34 (1): 13-25
40. Nishi A, Bibb JA, Matsuyama S et al. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem 2002; 81 (4): 832-841
41. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci USA 2000; 97 (23): 12840-12845
42. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997; 17 (21): 8147-8155
43. Rajasethupathy P, Vayttaden SJ, Bhalla US. Systems modeling: a pathway to drug discovery. Curr Opin Chem Biol 2005; 9 (4): 400-406
44. Romero E, Ali C, Molina-Holgado E, Castellano B, Guaza C, Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology 2006; 32 (8): 1791-1804
45. Sheng M, Hoogenraud CC. The postsynaptic architecture of excitatory synapses: A more quantitative view. Annu Rev Biochem 2007; 76 (1): 823-847
46. Snyder GL, Allen PB, Fienberg AA et al. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J Neurosci 2000; 20 (12): 4480-4488
47. Snyder GL, Fienberg AA, Huganir RL, Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32†kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 1998; 18 (24): 10297-10303
48. Snyder GL, Gaidi S, Fienberg AA, Allen P, Nairn AC, Greengard P. Regulation of AMPA receptor dephosphorylation by glutamate receptor agonists. Neuropharmacology 2003; 45 (6): 703-713
49. Stoof JC, Kebabian JW. Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum. Brain Research 1982; 250 (2): 263-270
50. Surmeier DJ, Bargas J, Hemmings Jr HC, Nairn AC, Greengard P. Modulation of calcium currents by a D1 dopaminergic protein kinase/ phosphatase cascade in rat neostriatal neurons. Neuron 1995; 14 (2): 385-397
51. Svenningsson P, Lindskog M, Ledent C et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 2000; 97 (4): 1856-1860
52. Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, Fisone G. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 1998; 84 (1): 223-228
53. Svenningsson P, Nishi A, Fisone G, Girault J-A, Nairn AC, Greengard P. DARPP-32: An integrator of neurotransmission. Ann Rev Pharmaco toxicol 2004; 44 (1): 269-296
54. Svenningsson P, Tzavara ET, Carruthers R et al. Diverse psychotomimetics act through a common signaling pathway. Science 2003; 302 (5649): 1412-1415
55. Tretter F, Scherer J. Schizophrenia, neurobiology and the methodology of systemic modeling. Pharmacopsychiatry 2006; 39 (Suppl. 1); S26-S35
56. Walaas S, Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci 1994; 4 (1): 84-98